Defining and treating the spectrum of intermediate-risk NMIBC - Abstract

PURPOSE: Low, intermediate and high risk categories have been defined to help guide the treatment of patients with nonmuscle invasive bladder cancer (Ta, T1, CIS).

However, while low and high risk disease has been well classified, the intermediate risk category has traditionally comprised a heterogeneous group that does not fit into either of these categories. As a result, many urologists remain uncertain about the categorization of patients as intermediate risk as well as the selection of the most appropriate therapeutic option for this patient population. In this study we examine current literature and clinical practice guidelines on intermediate risk nonmuscle invasive bladder cancer and, based on this review, provide urologists with a better understanding of this heterogeneous risk group as well as practical recommendations for the treatment of intermediate risk patients.

MATERIALS AND METHODS: The IBCG analyzed published clinical trials, meta-analyses and current clinical practice guidelines on intermediate risk nonmuscle invasive bladder cancer available as of September 2013. The definitions of intermediate risk, patient outcomes and guideline recommendations were considered, as were the limitations of the available literature and additional parameters that may be useful in guiding treatment decisions in intermediate risk patients.

RESULTS: Current definitions and management recommendations for intermediate risk nonmuscle invasive bladder cancer vary. The most simple and practical definition is that proposed by the IBCG and the AUA of multiple and/or recurrent low grade Ta tumors. The IBCG suggests that several factors should be considered in clinical decisions in intermediate risk disease, including number (greater than 1) and size (greater than 3 cm) of tumors, timing (recurrence within 1 year) and frequency (more than 1 per year) of recurrence, and previous treatment. In patients without these risk factors a single, immediate instillation of chemotherapy is advised. In those with 1 to 2 risk factors adjuvant intravesical therapy (intravesical chemotherapy or maintenance bacillus Calmette-Guérin) is recommended, and previous intravesical therapy should be considered when choosing between these adjuvant therapies. For those patients with 3 to 4 risk factors maintenance bacillus Calmette-Guérin is recommended. It is also important that all intermediate risk patients are accurately risk stratified at initial diagnosis and during subsequent followup. This requires appropriate transurethral resection of the bladder tumor, vigilance to rule out carcinoma in situ or other potential high risk tumors, and review of histological material directly with the pathologist.

CONCLUSIONS: Intermediate risk disease is a heterogeneous category, and there is a paucity of independent studies comparing therapies and outcomes in subgroups of intermediate risk patients. The IBCG has proposed a management algorithm that considers tumor characteristics, timing and frequency of recurrence, and previous treatment. Subgroup analyses of intermediate risk subjects in pivotal EORTC trials and meta-analyses will be important to validate the proposed algorithm and support clear evidence-based recommendations for subgroups of intermediate risk patients.

Written by:
Kamat AM, Witjes JA, Brausi M, Soloway M, Lamm D, Persad R, Buckley R, Böhle A, Colombel M, Palou J.   Are you the author?
Department of Urology, MD Anderson Cancer Center, Houston, Texas; Department of Urology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands; Department of Urology, AUSL Modena, Modena, Italy; Department of Urology, University of Miami School of Medicine, Miami, Florida; Department of Surgery, University of Arizona, and BCG Oncology, Phoenix, Arizona; Department of Urology/Surgery, Bristol Royal Infirmary & Bristol Urological Institute, Bristol, United Kingdom; Department of Urology, North York General Hospital, Toronto, Ontario, Canada; Department of Urology, HELIOS Agnes Karll Hospital, Bad Schwartau, Germany; Department of Urology, Claude Bernard University, Hôpital Edouard Herriot, Lyon, France; Department of Urology, Fundació Puigvert, Universitat Autònoma de Barcelona, Barcelona, Spain.  

Reference: J Urol. 2014 Mar 25. pii: S0022-5347(14)03041-9.
doi: 10.1016/j.juro.2014.02.2573

PubMed Abstract
PMID: 24681333 Bladder Cancer Section